Methods for Mediation Analysis with High-Dimensional DNA Methylation Data: Possible Choices and Comparison

Dylan Clark-Boucher[1], Xiang Zhou[2], Jiacong Du[2], Yongmei Liu[3], Belinda L Needham[4], Jennifer A Smith[4,5], Bhramar Mukherjee[2,4]

[1]Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
[2]Department of Biostatistics, University of Michigan, Ann Arbor, MI
[3]Department of Medicine, Divisions of Cardiology and Neurology, Duke University Medical Center, Durham, NC
[4]Department of Epidemiology, University of Michigan, Ann Arbor, MI
[5]Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI

Abstract

Epigenetic researchers often evaluate DNA methylation as a mediator between social/environmental exposures and disease, but modern statistical methods for jointly evaluating many mediators have not been widely adopted. We compare seven methods for high-dimensional mediation analysis with continuous outcomes through both diverse simulations and analysis of DNAm data from a large national cohort in the United States, while providing an R package for their implementation. Among the considered choices, the best-performing methods for detecting active mediators in simulations are the Bayesian sparse linear mixed model by Song et al. (2020) and high-dimensional mediation analysis by Gao et al. (2019); while the superior methods for estimating the global mediation effect are high-dimensional linear mediation analysis by Zhou et al. (2021) and principal component mediation analysis by Huang and Pan (2016). We provide guidelines for epigenetic researchers on choosing the best method in practice and offer suggestions for future methodological development.

Introduction

In this study, we review and evaluate the available methods for performing mediation analysis when the mediators are high-dimensional DNA methylation (DNAm) measurements. DNAm is an epigenomic mechanism describing when a methyl group binds to the DNA, which occurs predominantly at cytosine-guanine dinucleotides, called "CpG sites." DNAm has an important role in regulating gene expression across the entire genome, and is particularly impactful at CpG sites in the promoter regions of genes, where it can inhibit the binding of enzymes needed for transcription[1].

Recent advancements in technology have made it possible to collect DNAm data on a massive scale[2]. Indeed, microarray technologies have enabled the measurement of over 850,000 CpG sites simultaneously[2], encouraging broad research on DNAm in the etiology of disease; and studies taking advantage of these tools have identified DNAm as a risk factor in obesity[3,4], type II diabetes[5] and cardiovascular conditions[6,7]. At the same time, however, DNAm has also been linked to exposures such as diet[8], smoking[9], alcohol[10], air pollution[11], and socioeconomic status (SES)[12,13], which has prompted research on whether the effects of these exposures on health outcomes could be transferred by changes in

41 DNAm. Effect transmission of this nature is called *mediation*, and it has become popular in epigenomic
42 research to treat DNAm as a high-dimensional mediator between environmental exposures and human
43 disease[14].

44   As an example of such an analysis, our previous work[15,16] examined the association between low
45 SES and glycated hemoglobin (HbA1c) in the Multi-Ethnic Study of Atherosclerosis (MESA), a United
46 States population-based longitudinal study[17]. Indicators of SES, such as education level, are strong
47 predictors of type II diabetes[18], while HbA1c is an important risk factor of cardiovascular disease and a
48 critical biomarker in type II diabetes diagnosis[19–21]. Since education level is also associated with
49 DNAm[12,13,22], and DNAm itself with HbA1c level[23], we hypothesized that if low education results in
50 greater HbA1c, part of that effect could be mediated by DNAm (Fig. 1). In the current study, we revisit
51 this hypothesis for the purpose of illustration. Our sample from MESA has 963 individuals and includes
52 DNAm measurements at 402,339 CpG sites, none of which we know for certain are related to education
53 or HbA1c in advance.

54

55
56 **Fig. 1. Proposed causal mechanism in which the effect of low education on HbA1c is mediated by DNAm**

57

58   The standard statistical tool for addressing such a hypothesis is mediation analysis. Formally,
59 mediation is when an exposure, say A, affects an outcome, Y, in part through its effect on a single
60 mediating variable M. When M is a mediator of the A to Y association, the total effect of A on Y has two
61 components: an *indirect effect*, from A affecting M and M affecting Y, and a *direct effect*, from A affecting
62 Y independently of M. In the "traditional mediation analysis" approach proposed by Baron and Kenny
63 (1986), the associations from this mechanism could be measured by fitting a few regression models: one
64 for the effect of A on M (the mediator model), one for the effects of A and M on Y (the outcome model),
65 and sometimes a third model for the total effect of A on Y, M ignored[24–26]. The more recently developed
66 "causal mediation analysis," based on the counterfactual approach[27,28], has established conditions under
67 which the parameters of these models can be interpreted as causal effects[29]. The causal approach is more
68 flexible when Y or M are binary and when there is A-M interaction in the outcome model[30].

69
70

71   While standard examples of mediation consider only one exposure, one mediator, and one
72   outcome[31,32], there has been growing interest in methods for mediation that can handle many potential
73   mediators at once. Epigenetic studies have felt this need especially, as DNAm is usually measured at
74   several hundred thousand CpG sites with little prior knowledge of their importance. In settings such as
75   this, a naïve strategy would be to evaluate the potential mediators one at a time, each with their own pair
76   of models; but if the mediators are correlated this approach is inefficient, and the resulting estimates are
77   potentially biased due to confounding from the excluded co-mediators[31]. Instead, so that we leverage
78   these correlations rather than ignore them, the preferred approach is to assess the mediators jointly, in a
79   single multivariable model. Although several methods for fitting such a model have been presented in the
80   literature, none of them are widely used in analyzing DNAm data, a sign that epigenetic research is still
81   catching up to recent developments in mediation analysis with high-dimensional mediators.
82   Our study aims to bridge this gap and guide researchers in epigenetics to use state of the art
83   methods for mediation analysis with high-dimensional mediators. Despite the recent methodological
84   developments, there are no clear-cut standards for which methods should be applied in which
85   circumstances, making it difficult to select the best-suited method for an analysis in advance. While our
86   prior research examined methods for large scale single-mediator hypotheses[31], there is no such work for
87   methods that can incorporate many potential mediators at once. Our study addresses this question first
88   with an extensive simulation study, directly comparing the performance of sevesn different methods for
89   mediation with high-dimensional mediators across a spectrum of settings. Along with metrics related to
90   identification of key mediators and estimation of mediation effect, we include a computation time
91   comparison to evaluate the scalability of the methods to large datasets. Next, to assess the utility of these
92   methods on real data, we apply the same seven methods—plus two additional methods adapted from
93   them—on the data from MESA to evaluate the mediating role of DNAm in the association between low
94   education level and HbA1c. Our study is the first to address this critical gap in the epigenetic mediation
95   literature, both by providing clarity on the methods available and by assessing their strengths and
96   weaknesses under different settings. Moreover, although the analysis is centered around DNAm, the
97   methods we deploy are not specific to epigenetics, and our results and guidelines should be similarly
98   useful for researchers studying high-dimensional mediation problems in other fields. We include,
99   supplementary to our study, an R package for implementing the methods, called "hdmed," so that
100   researchers have access to a centralized resource they can draw from in their own high-dimensional
101   mediation analyses.
102
Notations and General Framework

104   Before proceeding, it will be useful to provide an overview of the relevant mediation model and
105   to summarize the types of methods which have become available. To begin, suppose we have a dataset of
106   n individuals: an exposure A_i, a continuous outcome Y_i, and continuous mediators M_i measured for the ith
107   person, i varying from 1 to n. We write M_i in bold to indicate its status as a vector—in this case, a set of p
108   mediators $M_i^{(j)}$, j varying from 1 to p. Let C_i be a vector of q covariates. When p is greater than 1, we can
109   use the regression models

$$E[Y_i|A_i, M_i, C_i] = \beta_a A_i + \boldsymbol{\beta_m^T} M_i + \boldsymbol{\beta_c^T} C_i \qquad (1)$$

111   and

$$E[M_i|A_i, C_i] = \boldsymbol{\alpha_a} A_i + \boldsymbol{\alpha_c} C_i \qquad (2)$$

113   to estimate the mediating role of M_i in the causal pathway between the exposure and outcome[33]. Model
114   (1) is the outcome model and model (2) is the mediator model. In model (1), $\boldsymbol{\beta_m}$ is a p-vector in which the

115   j^{th} component, $(\boldsymbol{\beta_m})_j$, is the linear association of jth mediator with Y_i adjusting for the other variables; while
116   β_a is the association between A_i and Y_i adjusting for mediators and covariates. In model (2), $\boldsymbol{\alpha_a}$ is a p-
117   vector of the associations between the exposure and each mediator, $(\boldsymbol{\alpha_a})_j$; and $\boldsymbol{\alpha_c}$ is a matrix with the
118   mediator-covariate associations. Also note that in model (1), we have assumed there is no interaction
119   between A_i and $\boldsymbol{M_i}$, which is beyond the scope of our present study.
120   The parameters of these models underly the causal effects of interest. Under certain
121   assumptions[27,33], the direct effect of A_i on Y_i is β_a, the global indirect effect (or global mediation effect) of
122   A_i on Y_i through $\boldsymbol{M_i}$ is $\boldsymbol{\alpha_a}^T\boldsymbol{\beta_m}$, and the total effect of A_i on Y_i is $\beta_a + \boldsymbol{\alpha_a}^T\boldsymbol{\beta_m}$. Another quantity of interest is
123   the proportion mediated, defined as the ratio of the global indirect effect to the total effect, which
124   measures the degree to which the A_i to Y_i pathway is mediated by $\boldsymbol{M_i}$. We may also seek to measure the
125   product terms $(\boldsymbol{\alpha_a})_j(\boldsymbol{\beta_m})_j$, which measure the contribution of the jth mediator to the global indirect effect,
126   since summing these for j from 1 to p yields $\boldsymbol{\alpha_a}^T\boldsymbol{\beta_m}$. However, we emphasize that $(\boldsymbol{\alpha_a})_j(\boldsymbol{\beta_m})_j$ cannot be
127   interpreted as a causal effect through the jth mediator on its own, since we have made no assumptions
128   about the causal ordering of the mediators and can only formally treat them as a joint system. Instead, we
129   call $(\boldsymbol{\alpha_a})_j(\boldsymbol{\beta_m})_j$ the *mediation contribution*, and describe the jth mediator as *active* if its contribution is not
130   zero.
131   If the potential mediators are uncorrelated, conditional on the exposure and covariates, or if p is
132   reasonably small relative to n, then it is trivial to fit the above models using linear regression. However, if
133   the mediators are correlated and p is large, the estimates from model (1) may have extremely high
134   variance; and if p is so large as to exceed n, the linear regression model cannot even be fitted. These
135   concerns are relevant to us because DNAm measurements tend to be correlated, while the number of sites
136   that we have measurements on exceeds the number of samples. Addressing these issues has been a focus
137   of the mediation literature, with authors using penalized regression[34–38], dimension reduction[39–41],
138   Bayesian inference[15,42], and latent variables[43] to make the outcome model statistically tractable.
139   We provide a graphical depiction of eleven available methods in Fig. 2, dividing them into **three**
140   different groups. Each method is described in greater detail in the Methods section and up to nine of them
141   are included in the analysis. In the first group, we consider methods that fit the above pair of models
142   explicitly, allowing one to estimate $\boldsymbol{\alpha_a}^T\boldsymbol{\beta_m}$, the global indirect effect, simply by summing the estimated
143   mediation contributions. These include high-dimensional mediation analysis (HIMA) by Zhang et al.
144   2016[34], high-dimensional mediation analysis (HDMA) by Gao et al. 2019[35], mediation analysis via fixed
145   effect model (MedFix) by Zhang 2019[36], pathway least absolute shrinkage operator (pathway LASSO) by
146   Zhao and Luo 2022[37], the Bayesian sparse linear mixed model (BSLMM) by Song et al. 2020[15], and the
147   Gaussian mixture model (GMM) by Song et al. 2021[42]. In the second group, we consider methods that
148   can estimate $\boldsymbol{\alpha_a}^T\boldsymbol{\beta_m}$ "directly"; in other words, without needing to fit the original pair of models explicitly.
149   These have the drawback of being unable to identify specific active mediators because they do not
150   provide estimates of the mediation contributions. They include principal component mediation analysis
151   (PCMA) by Huang and Pan 2016[39], sparse principal component mediation analysis (SPCMA) by Zhao et
152   al. 2020[40], and high-dimensional linear mediation analysis (HILMA) by Zhou et al. 2021[38]. Last, in the
153   third group, we consider methods that make no attempt to estimate the mediation effects as originally
154   proposed, but instead reconceptualize the mediation framework with newly-defined parameters based on
155   latent variables. This group includes the methods high-dimensional multivariate mediation analysis
156   (HDMM) by Chén et al. 2018[41] and latent variable mediation analysis (LVMA) by Derkach et al. 2021[43].
157   Within this comparative structure, we evaluate methods from all three groups, identifying their strengths
158   and weaknesses across a wide range of simulation settings and analysis of DNAm data from MESA.

159

160

161

Fig. 2. Methods for mediation analysis with high-dimensional DNAm data. Figure describes eleven methods for
mediation analysis that can be applied to high-dimensional DNA methylation data, each of which is described in
greater detail in the Methods section. Seven of these methods are included in the simulation study and nine in the

165   observed DNAm data analysis with MESA. Group 1 methods fit the outcome model explicitly using penalized
166   regression or Bayesian regresion; Group 2 methods obtain the global mediation effect without fitting the original
167   outcome model explicitly; and Group 3 methods measure mediation through latent variables.

168

Results

Simulation Results

171   We begin by comparing the performance of the methods using simulations, where we know and
172   can control the true values of the parameters. On simulated data with 2,000 (potential) mediators and
173   either 1,000 or 2,500 observations, we consider (1) a baseline setting, where the mediators are moderately
174   correlated and their signals are sparse; (2) a high-correlation setting, where the correlations between
175   mediators are enhanced compared to (1); and (3) a non-sparse setting, where every mediator has at least
176   some mediation signal but some of the signals are systematically larger. In Settings (1) and (2), 60
177   random mediators have $(\alpha_a)_j$ only sampled from a Normal(0,1), 60 have $(\beta_m)_j$ only sampled from a
178   Normal(0,1), and 20 have both, with the remaining entries of α_a and β_m fixed at zero. In Setting (3), we
179   use a similar scheme, but sample the previously zero $(\alpha_a)_j$ and $(b_m)_j$ from a Normal$(0,0.2^2)$. Our
180   simulations also vary the strength of the signals within each of these settings by changing the proportion
181   of variance that is explained by the associations. We do so by changing PVE_A, the proportion of variance
182   in each mediator that can be explained by A, among those mediators that are affected by A; PVE_{IE}, the
183   proportion of variance of Y that is explained by the total mediation effect; and PVE_{DE}, the proportion of
184   variance of Y that is explained by the direct effect of A on Y. Results for varying PVE_{IE} are presented here
185   while results for varying PVE_{DE} and PVE_A are included in the supplement (Supplementary Figs 1-4). In
186   addition to the high-dimensional mediation methods, we include a one-at-a-time method[44] in which the
187   mediators are assessed individually using linear regression. We evaluate the methods by their true
188   positive rate (TPR) for detecting active mediators, their mean squared error (MSE) for estimating the
189   contributions of active and inactive mediators, and their percent relative bias for estimating the global
190   indirect effect. See Methods for more details.

191

True positive rate

193   Fig. 3 compares the TPR detecting active mediators of the Group 1 methods and the one-at-a-time
194   method. The value shown is the mean TPR over 100 simulated datasets and a 95% empirical confidence
195   interval (CI). On each dataset and for each method, thresholding was used to keep the false discovery rate
196   (FDR) below 10%. For the non-sparse setting, we show the TPR for detecting mediators whose $(\alpha_a)_j$ and
197    $(\beta_m)_j$ were both sampled from Normal(0,1) rather than Normal$(0,0.2^2)$. We include the Group 1 methods
198   HIMA, HDMA, MedFix, pathway LASSO, and BSLMM. We focus on TPR but not false positive rate
199   (FPR) because the FDR correction was highly conservative, the mean FPR ranging from 0 to 5.1×10^{-4}
200   across all settings and methods.

201   For a sample size of 2,500 and a PVE_{IE} of 0.10, the most powerful method in the baseline setting
202   was BSLMM (mean TPR: 0.45; CI: 0.25 - 0.63), whose average TPR was 40% higher than that of the
203   second-best method, HDMA. BLSMM also performed best when PVE_{IE} was 0.05 (mean TPR: 0.25; CI:
204   0.02 - 0.48), but to a lesser degree, outperforming HDMA by only 13%. BSLMM remained the best
205   method, and HDMA the second best, no matter the signal strength or the degree of correlations, but
206   performed poorly when the signals were non-sparse. In the setting with 1,000 observations, PVE_{IE} set to

207   0.05, and non-sparse signals, the best-performing method was HIMA (mean TPR: 0.09; CI: 0.05 - 0.10),
208   its average TPR 3.3 times higher than that of BSLMM, which performed worst.
209

Fig. 3. True positive rate for detecting mediation signals at a false discovery rate of 10%. Value shown is the
mean TPR across 100 simulated data replicates, with intervals representing the inner 95% range. In the baseline and
high-correlation-among-mediators settings, TPR is for distinguishing mediators which contribute to the global
mediation effect from those which do not, whereas in the non-sparse setting, TPR is for distinguishing mediators
whose contributions were sampled from a high-variance distribution from those whose contributions were sampled
from a low-variance distribution. False discovery proportion was capped below 10% by a proper choice of the p-
value threshold (one-at-a-time, HIMA, HDMA, MedFix), posterior inclusion probability threshold (BSLMM), or
method tuning parameter (pathway LASSO).

218

Estimation of contributions of active mediators

Next, we assess the MSE of the methods for estimating mediation contributions, relative to the one-at-a-
time approach. In Fig. 4, we show the relative MSE (rMSE) for estimating mediation contributions
among the mediators that were either active (in the baseline and high-correlation settings) or had $(\alpha_a)_j$ or
$(\beta_m)_j$ sampled from the larger-variance distribution (in the non-sparse setting). In the baseline setting with
2,500 observations, the best-performing method when the mediation signal was strong was BSLMM,
whose mean rMSE of 0.59 (CI: 0.13 - 1.51) was 24% lower than that of HDMA, the second-best method.
However, when the PVE_{IE} was reduced to 0.05 or the sample size reduced to 1,000, the best-performing
method was either HDMA or MedFix, with MedFix (mean rMSE: 0.79; CI: 0.31 - 1.53) performing 61%

228 better than BSLMM after reducing both. Similar trends were observed for the high-correlation and non-
229 sparse settings.

230

Fig. 4. MSE in estimating mediation contributions of active mediators, relative to one-at-a-time method. Y-
axis is on a $\log_{10}$ scale. Value shown is the mean of the relative mean-squared error for estimating mediation
contributions among active mediators (relative to the one-at-a-time approach) across 100 simulated data replicates,
with intervals representing the inner 95% range. For baseline and high-correlation-between-mediators settings,
active mediators which contribute to the global mediation effect, whereas in the non-sparse setting, active mediators
are those whose contributions were sampled from a distribution with large variance instead of small.

Estimation of contributions of inactive mediators

239 Figure 5 shows the rMSE among the mediators that either were not active (in the baseline and
240 high-correlation settings) or had $(\alpha_a)_j$ or $(\beta_m)_j$ sampled from the smaller-variance distribution (in the non-
241 sparse setting). We exclude pathway LASSO from Fig. 4 because for the baseline and high-correlation
242 settings it had rMSEs of exactly zero. The reason for this is that pathway LASSO tended to be highly
243 conservative and successfully assigned inactive mediators to have no effect. As for the other methods, in
244 the baseline setting with 2,500 samples, MedFix performed the best when PVE_{IE} was 0.10, with a mean
245 rMSE of 1.8×10^{-3} (CI: 1.9×10^{-4} - 6.4×10^{-3}), which was 46% lower than the mean rMSE for the second-best
246 method, HIMA. In contrast, HIMA was the best-performing method when signal was weakened to a
247 PVE_{IE} of 0.05, attaining a mean rMSE of 2.8×10^{-4} (CI: 0.0 - 1.3×10^{-3}), which was 94% lower than that of
248 the second-best, MedFix. Results were similar when the correlations between mediators were heightened
249 and when the sample size was reduced. In the settings where mediation signals were non-sparse, the best-

250   performing method was always HIMA, which had a mean rMSE of 3.7×10^{-2} (CI: 1.1×10^{-2} - 6.5×10^{-2})

251   when PVE_{IE} was 0.10 and there were 2,500 observations, 2% lower than that of MedFix.

252

Fig. 5. MSE in estimating mediation contributions of inactive mediators, relative to one-at-a-time method.
Y-axis is on a $\log_{10}$ scale. Value shown is the mean of the relative mean-squared error for estimating mediation
contributions among inactive mediators (relative to the one-at-a-time approach) across 100 simulated data replicates,
with intervals representing the inner 95% range. For baseline and high-correlation-between-mediators settings,
inactive mediators are those which do not contribute to the global mediation effect, whereas in the non-sparse
setting, inactive mediators are those whose contributions were sampled from a distribution with small variance
instead of large.

260

Estimation of global indirect effect

262   Lastly in Fig. 6, we show the percent relative bias for estimating $\alpha_a^T \beta_m$, the global indirect effect.
We use the same methods as in Figures 3 to 5 along with the Group 2 methods PCMA and HILMA,
which obtain an estimate of the global indirect effect without needing to directly fit the original mediation
model. (The Group 2 method SPCMA is excluded for computational reasons.) In the baseline setting with
2,500 samples, the best performer when PVE_{IE} was 0.10 was HILMA, whose mean relative bias of 9%
(CI: 0.6% - 20.8%) was 40% lower than that of HDMA, the second-best. Next, when the PVE was
reduced to 0.05, the best-performing method was MedFix (mean relative bias: 20.5%; CI: 1.0% - 43.8%),
which outperformed HILMA by only 7%. We observed similar results for a sample size of 1,000 and
high-correlations. In the non-sparse settings, where the biases tended to be much higher, the best
performing methods were either PCMA or HDMA.

272
273

Fig. 6. Percent relative bias in estimated global indirect effect. Value shown is the mean of the percentage relative bias in estimating the global mediation effect across 100 simulated data replicates, with intervals representing the inner 95% range.

277

Scalability

We evaluated the scalability of the methods by running them 30 times on a common computing platform, and recording their run time (Table 1). This was done in both a small data setting ($n = 100$, $p = 200$) and a big data setting ($n = 1,000$, $p = 1,000$). On the larger dataset, the methods MedFix, HDMA, and PCMA posed insignificant computational burden; whereas BSLMM took an average of 40.1 minutes per run (assuming 30,000 posterior samples), HILMA an average of 40.9 minutes per run, pathway LASSO an average of 192.6 minutes per run, and SPCMA an average of 842.5 minutes per run (assuming 100 principal components). Run times were substantially lower in the smaller dataset, the slowest method, pathway LASSO, only taking an average of 18.71 minutes. The memory consumption of the methods is included in Supplementary Table 1.

288
289
290
291
292
293
294

295

296

297 **Table 1. Computation time comparison for high-dimensional mediation analysis methods**

Method	$n = 100, p = 200$		$n = 1,000, p = 2,000$	
	Mean	Interquartile Range	Mean	Interquartile Range
BSLMM	39.17s	(38.84s - 39.54s)	40.14m	(39.74m - 40.34m)
HDMA	1.40s	(1.37s - 1.40s)	29.76s	(29.55s - 29.92s)
HDMM	24.85s	(24.80s - 24.89s)	12.36m	(12.33m - 12.37m)
HILMA	24.42s	(24.13s - 24.63s)	40.85m	(38.22m - 40.65m)
HIMA	0.25s	(0.25s - 0.25s)	3.55s	(3.47s - 3.62s)
MEDFIX	0.61s	(0.60s - 0.61s)	7.33s	(7.22s - 7.42s)
PCMA	2.77s	(2.74s - 2.79s)	58.97s	(58.08s - 59.35s)
PLASSO	18.71m	(18.19m - 19.23m)	192.62m	(188.10m - 195.83m)
SPCMA	16.05m	(15.94m - 16.04m)	842.54m	(827.26m - 855.21m)

298 Methods were run 30 times each on a single core of an Intel(R) Xeon(R) Gold 6242R CPU @ 3.10GHz processor.

299

DNAm data analysis results from MESA

301   For our real data analysis, we applied the methods on a dataset with high-dimensional epigenetic
302 mediators. Our exposure of interest was low SES—measured by educational attainment below a four-year
303 degree—while our outcome variable was HbA1c level and our potential mediators were DNAm
304 measurements at 402,339 CpG sites. Since the methods are incapable of handling so many CpG sites at
305 once, we reduced our scope to only include the 2,000 sites with the strongest association with low SES.
306 This was based on a linear mixed-model adjusting for age, sex, race, and the estimated proportions of
307 residual non-monocytes as fixed effects and methylation chip and position as random effects. Our final
308 dataset contained these 2,000 CpG sites and 963 samples. HbA1c, DNAm, and all other continuous
309 variables were standardized prior to analysis.

310

Identification of noteworthy CpG sites

312   We identified CpG sites that potentially mediated the relationship between low SES and HbA1c
313 using the Group 1 methods HIMA, HDMA, MedFix, pathway LASSO, and BSLMM. In HIMA, HDMA,
314 MedFix, and pathway LASSO, which involve feature selection, we describe a CpG site to be "active" if
315 its estimated mediation contribution is not zero; whereas in BSLMM, we do so if the estimated posterior
316 inclusion probability is not zero (see Methods). We also included a one-at-a-time method in which the
317 CpG sites were assessed individually with linear mixed models, identifying active mediators with the
318 joint significance test[44]. Out of 2,000 CpG sites, HIMA found 3 sites to be noteworthy, HDMA found 11,
319 MedFix found 3, pathway LASSO found 141, and BSLMM found 3, amounting to 144 unique CpG sites
320 in total. The one-at-a-time method identified zero CpG sites as noteworthy at an FDR threshold of 10%.
321 Eleven CpG sites were identified as noteworthy by at least two of the methods (Table 2). Among these
322 11, the estimated mediation contributions were similar across methods in direction and size except for
323 BSLMM, for which the estimates were an order of magnitude smaller than the others but in the same
324 direction.

325

326

327

328

329

330

331

332

Table 2. Estimated contributions of noteworthy CpG sites on the mediation pathway between low education and HbA1c

CpG Name	Chromosome	Nearby Gene(s)	USCS RefGene Group	Univariate (0 sites identified)	HIMA (3 sites identified)	HDMA (11 sites identified)	MedFix (3 sites identified)	Pathway LASSO (141 sites identified)	BSLMM (3 sites identified)
cg10508317	17	*SOCS3*	Body	3.48 x10^{-2}	1.59 x10^{-2}*	3.56 x10^{-2}*	2.90 x10^{-2}*	2.35 x10^{-2}*	0.25 x10^{-2}
cg01288337	14	*RIN3*	Body	3.35 x10^{-2}	1.47 x10^{-2}*	2.82 x10^{-2}*	2.70 x10^{-2}*	4.43 x10^{-2}*	0.21 x10^{-2}
cg10244976	16	*LMF1*	Body	3.00 x10^{-2}	0	2.78 x10^{-2}*	0	2.23 x10^{-2}*	0.19 x10^{-2}
cg07516252	14	*REC8*	TSS200	2.72 x10^{-2}	0	2.24 x10^{-2}*	0	2.26 x10^{-2}*	0.26 x10^{-2}
cg07571519	10	*C10orf105*; *CDH23*	3'UTR; Body	2.53 x10^{-2}	0.33 x10^{-2}*	3.67 x10^{-2}*	1.47x10^{-2}*	2.81 x10^{-2}*	0.21 x10^{-2}
cg23079012	2	*LINC00299*	Body	2.27 x10^{-2}	0	1.99 x10^{-2}*	0	1.98 x10^{-2}*	0.29 x10^{-2}
cg01587454	8	*DCAF4L2*	1stExon	1.77 x10^{-2}	0	2.10 x10^{-2}*	0	1.99 x10^{-2}*	0.38 x10^{-2}
cg27527503	4	*HADH*	TSS1500	1.75 x10^{-2}	0	1.86 x10^{-2}*	0	1.27 x10^{-2}*	0.23 x10^{-2}
cg25891647	11	*GRAMD1B*	Body	-1.27 x10^{-2}	0	-3.42 x10^{-2}*	0	-3.02 x10^{-2}*	-0.33 x10^{-2}
cg08473752	17	*NLK*	Body	-0.70 x10^{-2}	0	-2.34 x10^{-2}*	0	-2.32 x10^{-2}*	-0.22 x10^{-2}
cg12644059	15	*BLM*	N/A[1]	-0.03 x10^{-2}	0	-2.31 x10^{-2}*	0	-1.84 x10^{-2}*	-0.22 x10^{-2}

335 *Selected as noteworthy by given method

336 [1]CpG site cg12644059 is 3.240kb from the final base pair of the BLM gene

337 Table includes all CpG sites that were selected as having a noteworthy mediation contribution by at least two of the

338 implemented methods out of 2,000 CpG sites in total. Criteria for CpG identification varied by method. All

339 estimates are adjusted for age, sex, race, and the estimated proportions of residual non-monocytes as fixed effects,

340 along with methylation chip and position as random effects to address potential batch effects. Note that for HIMA,

341 HDMA, MedFix, and pathway LASSO, which fit high-dimensional regression models, we used additional pre-

342 screening to reduce the number of mediators in advance to only $n/\log(n) \approx 141$ CpG sites, which is the approach

343 recommended by the HIMA and HDMA authors and helps with statistical and computational efficiency (see

344 Methods). Pathway LASSO selected all of these 141.

345

346   Some of these CpG sites were on or nearby genes that are potentially related HbA1c. Site

347 cg10508317 is in the body of the *SOCS3* gene, for which a rich body of literature has established links

348 between overexpression and insulin resistance[45]. The same site has also been identified in MESA as a

349 mediator between adult SES and BMI[46] and adult SES and HbA1c[31] based on previous one-at-a-time

350 analyses. Site cg01288337, in the body of the *RIN3* gene, has been identified in MESA as a potential

351 mediator between adult SES and HbA1c based on one-at-a-time analysis as well[31]. The *RIN3* gene itself is

352 proximal to the *SLC24A4* gene, both of which have been linked to brain glucose metabolism in human

353 population studies[47]. In addition, site cg27527503 is in the promoter region of the *HADH* gene, which is

354 differentially expressed with respect to diabetes status[48] and is a primary driver of hyperinsulinism[49] and

355 hyperinsulinaemic hypoglycemia (low blood sugar due to excess insulin)[50]. A Venn diagram of genes

356 identified by the methods is included in Supplementary Fig. 5, and results for every noteworthy CpG site

357 are listed in Supplement File 1.

358

Global mediation through DNAm

360   Next, we estimated the direct effect of low education on HbA1c, the global indirect effect of low

361 education on HbA1c through DNAm, and the total effect of low education on HbA1c using the Group 1

362   methods HIMA, HDMA, MedFix, pathway LASSO, and BSLMM, as well as the Group 2 methods

363   PCMA, SPCMA, and HILMA (Table 3). Results across methods varied considerably, with the estimated

364   global indirect effect ranging from 0.03 in HILMA to 0.17 in SPCMA. The estimated total effect ranged

365   from 0.02 (HILMA) to 0.198 (HIMA, HDMA, and MedFix). While HILMA appeared to be an outlier,

366   some of the other methods were consistent, with HDMA, BSLMM, P- LASSO, PCMA, and SPCMA all

367   estimating the global indirect effect to be close to 0.15. The variability in the estimated indirect effect and

368   estimated total effect led to variability in the proportion mediated as well, from 17.1% in HIMA to 100%

369   in HILMA.

370

371   **Table 3. Estimated effects in the mediation mechanism from low education to DNAm to HbA1c**

Method	Estimated Global indirect Effect	Estimated Direct Effect	Estimated Total Effect	Estimated Proportion Mediated
HIMA	0.03	0.16	0.20	0.17
HDMA	0.13	0.07	0.20	0.65
MedFix	0.07	0.13	0.20	0.36
BSLMM	0.14	0.05	0.18	1.00
Pathway LASSO	0.13	0.05	0.18	0.74
PCMA	0.15	0.02	0.17	0.91
SPCMA	0.17	0.00	0.17	1.00
HILMA	0.03	0.00	0.03	1.00

372   All estimates are adjusted for age, sex, race, and the estimated proportions of residual non-monocytes as fixed

373   effects, along with methylation chip and position as random effects to address potential batch effects. We provide

374   only point estimates, not interval estimates, because some of the methods are either not capable of producing

375   interval estimates or do not provide the code for producing them in their software. For HIMA, HDMA, and MedFix,

376   which as coded do not directly provide estimates of the direct effect, we first estimate the total effect by fitting the

377   outcome model with the CpG sites omitted, then estimate the direct effect by subtracting the indirect effect from the

378   total effect. Note also that, for HIMA, HDMA, MedFix, and pathway LASSO, we used additional screening to

379   reduce the number of mediators in advance for the sake of statistical and computational efficiency, so only n/log(n)

380   ≈ 141 CpG sites were seen by the multivariate model rather than 2,000 (this approach is recommended by the HIMA

381   and HDMA authors).

382

383   **Additional Findings**

384   In addition to estimating the global indirect effect, method SPCMA is also able to identify

385   potentially-mediating CpG sites in groups. It does so by linearly combining the mediators using sparse

386   principal component-defined weights, then evaluating the resulting principal components as mediators

387   themselves[40]. However, out of 100 computed principal components, only three of them had significant

388   mediation contributions after 10% FDR correction, the first representing a linear combination of 762 CpG

389   sites, the second a combination of 782 sites, and the third a combination of 797 sites. Since the

390   transformed mediators are functions of so many CpG sites at once, one cannot make claims about which

391   particular CpG sites are active mediators, but the method still provides insight to whether there is

392   statistical mediation at all.

393   We finish our analysis by deploying HDMM, a method from Group 3. Unlike the methods in

394   Groups 1 and 2, HDMM cannot be used to estimate the global indirect effect from the proposed mediation

395   structure, nor to estimate the mediation contributions of specific CpG sites. Rather, HDMM uses a

396   likelihood-based approach to compute "directions of mediation", which are weights that can be used to

397   linearly combine the observed mediators into unobserved, latent mediators that replace the observed

398   mediators in the mediation models (similar to PCMA). The estimated effect of the first latent mediator on

399 average HbA1c was 0.13, the estimated total effect 0.71, and the proportion mediated 0.715. The three
400 CpG sites with the largest directions of mediation were cg01288337 (0.36) on the *RIN3* gene,
401 cg16162970 (-0.22) near the *PACS2* gene, and cg25891647 (-0.21) on the *GRAMD1B* gene; the first and
402 last of which were among the 11 CpG sites identified by other methods in Table 2. Although the size and
403 direction of these estimates are not interpretable, they offer evidence that these CpG sites are potentially
404 involved in mediation.
405

Discussion

407 In this study, we reviewed and evaluated statistical methods for performing mediation analysis with high-
408 dimensional DNAm data, so that researchers in epigenetics have the information they need to choose the
409 most appropriate method for their data sample, subject matter, and research objectives. In extensive
410 simulations, we found that the most powerful method for identifying active mediators was generally
411 BSLMM, with HDMA close behind; though the former performed poorly in settings where the mediation
412 signals were non-sparse. No method was uniformly better than the others at estimating the mediation
413 contributions, though pathway LASSO was always the weakest. For estimating the global indirect effect,
414 the best-performing method was HILMA in sparse mediation settings and PCMA or HDMA in non-
415 sparse settings. Our scalability comparison revealed that HIMA, HDMA, MedFix, and PCMA were easily
416 scalable to large datasets (e.g., $n = 1,000$ and $p = 2,000$), whereas SPCMA and pathway LASSO were
417 extremely computationally costly.
418   On DNAm data from MESA, 11 CpG sites were selected by at least two of the methods as
419 mediators between low SES and HbA1c level. Of the many genes related to these sites, *SOCS3*, *RIN3*,
420 and *HADH* have the strongest potential biological connections to HbA1c[45,47,48,50–52], which contributes to
421 the already rich literature on DNAm as a mediator between the exposome and health outcomes.
422 Moreover, the methods generally produced similar estimates of the mediation contributions, with the
423 exception of BSLMM. It is possible that since BSLMM is non-sparse, the estimated mediation
424 contributions end up severely shrunken compared to the methods which directly select features.
425   Estimates of the global indirect effect were highly variable. Part of this can be explained by the
426 fact that HDMA, MedFix, HIMA, and pathway LASSO are sparse models that can set mediation
427 contributions to be exactly zero, resulting in a rigid and unstable estimation of the global indirect effect.
428 The method HILMA, which is built specifically for estimating the global indirect effect and direct effect,
429 produced estimates that were sharply different than the other methods, possibly because our simulations
430 indicated that it struggled in non-sparse mediation settings.
431   In practice, the optimal method for mediation analysis with high-dimensional mediators will
432 depend both on the data and the objective. If the goal is to identify specific CpG sites that are involved in
433 mediation, one preferred method may be HDMA, which performed well at detecting active mediators in
434 our simulations and was not overly conservative when applied to the observed data. If one's focus is the
435 global indirect effect, our simulations suggested that the optimal method is HILMA; but considering the
436 variability we observed in our DNAm analysis, it may be worthwhile to apply BSLMM and HDMA as
437 well to ensure the results are robust. If the results of multiple methods disagree substantially, it may be
438 difficult to say with confidence which is closest to the truth, and the estimates should be interpreted with
439 caution. Next, if there is interest in latent, unmeasured mediators, either HDMM or LVMA is worth
440 attempting, though HDMM is computationally simpler. A detailed decision tree for selecting the optimal
441 method is included in Fig. 7.
442

443

444

Fig. 7. Decision tree for selecting a high-dimensional mediation analysis.

446

Some strengths of our study include its broad coverage of the available methods, the breadth of
its simulation settings, and the comprehensive set of evaluation criteria. Our analysis of real DNAm data
is especially essential because it elucidates the potential limitations of using these methods in practice, as
it is impossible to incorporate the full complexity of real data sources into contrived simulation settings.
However, our study also has weaknesses. First, since DNAm measurements and HbA1c data were
collected concurrently, and represent only single time points, we cannot interpret the parameters we have
estimated as causal effects. Nor can we interpret the mediation contributions estimated in Table (2) as
causal, since DNAm was correlated across CpG sites and we have made no assumptions about their
causal ordering. Moreover, although it would be optimal to address our research question longitudinally,
with measurements at multiple time points, there is a dearth of mediation analysis methods which can
handle that type of data, and longitudinal mediation analysis with high-dimensional mediators should be a
focus of future methodological development. Second, we limited our analysis to the situation that Y and
M are continuous, that **M** and A do not interact, and that only one A is of interest. However, we note that
the methods HIMA and HDMA can also be applied to identify active mediators when Y is binary, while
PCMA can be applied to infer the global indirect effect when there is A-**M** interaction in the outcome
model. MedFix, along with the simultaneously-proposed MedMix (mediation analysis with mixed effect
model by Zhang (2021)) can be applied when both the exposures and mediators are high-dimensional,

464 while Huang and Vanderweele (2014) proposed a variance component test of the global indirect effect

465 when only A is high-dimensional[53]. As the landscape of methods for high-dimensional mediation analysis

466 continues to expand, future review studies should consider exploring additional mediation settings (in

467 presence of non-linearity, interaction) for which statistical methods are continuing to become available.

468

469 # Methods

470 ## Mediation Model with Multiple Mediators

471 Let M be a set of p variables, $M^{(1)}$, $M^{(2)}$, to $M^{(p)}$, each a potential mediator in the causal pathway between

472 A and Y. We assume that the ordering of the potential mediators is arbitrary and that Y is continuous.

473 Given a dataset of n individuals, with A_i, Y_i, M_i, and q covariates C_i measured for each subject i, we can

474 evaluate the mediating role of M with the models

475
$$E[Y_i|A_i, M_i, C_i] = \beta_a A_i + \beta_m^T M_i + \beta_c^T C_i \qquad (1)$$

476 and

477
$$E[M_i|A_i, C_i] = \alpha_a A_i + \alpha_c C_i. \qquad (2)$$

478 We refer to these as the outcome and mediator models. Bolded terms distinguish vectors from

479 scalars. Under certain assumptions, the parameters of this model can be used to derive causal effects of

480 interest: Namely, in addition to the baseline assumption of temporality, we assume (1) that there is no

481 unmeasured confounding in the exposure-outcome association after conditioning on C, (2) that there is no

482 unmeasured confounding in the mediator-outcome associations after adjusting for the exposure and C, (3)

483 that there is no unmeasured confounding of the exposure-mediator associations after conditioning on C,

484 and (4) that the measured confounders of the mediator-outcome associations are not caused by the

485 exposure (which would make those confounders mediators themselves). In these circumstances only can

486 β_a be interpreted as the natural direct effect of A on Y, $\alpha_a^T \beta_m$ the natural indirect effect of A on Y through

487 M, and $\beta_a + \alpha_a^T \beta_m$ the total effect of A on Y[33]. We say a mediator $M^{(j)}$ is *active* if $(\alpha_a)_j (\beta_m)_j$ is not zero,

488 since it contributes mathematically to the indirect effect, but this contribution itself cannot be formally

489 interpreted causally unless the mediators are independent conditional on A and C. Extensions of this

490 framework cover cases when Y is binary, when M is binary, or when the outcome model requires an

491 interaction effect between M and A[33].

492 A summary of the methods that can evaluate M as a mediator is provided in Table 4, using the

493 above pair of models as a frame of reference. We describe each of the methods in greater detail in the

494 following three sections.

495

496 **Table 4. Methods Summary.**

Name and Author	Estimation of global indirect effect	Estimation of mediation contributions	Mediator identification	Y Data Type	Summary
Group 1 Methods					
HIMA; Zhang, 2016	Point estimation	Point estimation	Yes	Continuous or binary	Fits the outcome model with the minimax concave penalty. Requires subsequent fitting of ordinary least squares regression to test the statistical significance the mediation contributions.
HDMA; Gao, 2019	Point estimation	Point, interval estimation	Yes	Continuous or binary	Fits the outcome model with the de-sparsified LASSO penalty.
MedFix; Zhang, 2021	Point estimation	Point, interval estimation	Yes	Continuous	Fits the outcome model with the adaptive LASSO penalty. Can also be applied when the exposure is high-dimensional in addition to the mediators.
Pathway LASSO Zhao and Luo, 2022	Point estimation	Point estimation	Yes	Continuous	Fits the outcome model and mediator models with a jointly penalized likelihood, directly applying shrinkage to the mediation contributions $(\alpha_a)_j (\beta_m)_j$.
BSLMM; Song, 2020	Bayesian point, interval estimation	Bayesian interval estimation	Yes	Continuous	Bayesian mixed-model in which the mediator-outcome associations $(\beta_m)_j$ and the exposure-mediator associations $(\alpha_a)_j$ are assumed to independently follow sparse normal distributions.
GMM; Song, 2021	Bayesian point, interval estimation	Bayesian interval estimation	Yes	Continuous	Bayesian mixed-model in which the mediator-outcome associations $(\beta_m)_j$ and the exposure-mediator associations $(\alpha_a)_j$ are assumed to jointly follow a sparse multivariate normal distribution.
Group 3 Methods					
PCMA; Huang and Pan, 2016	Point, interval estimation	No	No	Continuous or binary	Applies principal component analysis on the mediator model residuals, transforming the mediators so they are independent. Can be applied when there is A-$\boldsymbol{M}$ interaction in the outcome model.
SPCMA; Zhao, 2019	Point, interval estimation	No	Identifies whether subsets of the mediators are jointly active	Continuous	Similar to PCMA but applies sparse PCA, resulting in transformed mediators that are more interpretable.
HILMA; Zhou, 2020	Point, interval estimation	No	No	Continuous	Uses a debiased penalized regression approach to directly estimate the global indirect effect $\alpha_a^T \beta_m$. Can be applied for multiple exposures simultaneously.
Group 3 Methods					
HDMM; Chen, 2018	No	No	Nonspecifically identifies groups of active mediators	Continuous	Estimates "directions of mediation" by which the observed mediators can be linearly combined to form latent mediators. The latent mediators replace the true mediators in the analysis.
LVMA; Derkach, 2019	No	No	Identifies inputted mediators associated with latent mediators	Continuous or binary	Reformulates the causal structure of the mediation problem. Assumes that $\boldsymbol{M}$ itself is not responsible for mediation, but rather that the effect of A on Y is mediated by latent, unmeasured factors, $\boldsymbol{F}$, which also cause changes in $\boldsymbol{M}$.

497

Group 1 Methods

This group of methods can estimate both the global indirect effect $\alpha_a{}^T\beta_m$ and the mediator-specific contributions $(\alpha_a)_j(\beta_m)_j$, j from 1 to p.

HIMA

High-dimensional mediation analysis (HIMA), proposed by Zhang et al. (2016), is a penalized regression approach with two main steps: First, the outcome model is fitted with a minimax concave penalty[54], performing feature selection on the mediators by setting some of them to have no effect on Y[34]. Then, among the remaining mediators, they fit the mediator models individually using ordinary regression. The authors test the significance of $(\alpha_a)_j(\beta_m)_j$ by applying Bonferroni correction to the maximum of the $(\beta_m)_j$ and $(\alpha_a)_j$ p-values. To obtain p-values for the $(\beta_m)_j$ estimates, the authors re-fit the reduced outcome model by ordinary least squares, which statistically may be overconfident. The authors also recommend an initial screening step to reduce the number of mediators at the start, as the outcome model will still be unstable if p is extremely large compared to n.

HDMA

High-dimensional mediation analysis (HDMA), proposed by Gao et al. (2019), is the same as HIMA except for its penalty function, replacing the minimax concave penalty with the recently-proposed de-sparsified LASSO[35,55]. The advantage of this penalty is that the resulting estimates of β_m are asymptotically normal, so one can test their statistical significance without needing to subsequently apply ordinary least squares. HDMA is also less biased than HIMA when the mediators are highly-correlated.

MedFix

Mediation analysis via fixed effect model (MedFix) is another extension of HIMA, proposed by Zhang (2021)[36]. MedFix was originally proposed for a setting where there are not only multiple mediators, but also multiple exposures, which it handles by applying adaptive LASSO to both the outcome model and the mediator models. If there is only one exposure, feature selection in the mediator models is not necessary, and applying MedFix is analogous to applying HDMA except with adaptive LASSO instead of debiased LASSO.

Pathway LASSO

Pathway LASSO is another penalized regression approach, proposed by Zhao and Luo (2022)[37]. Whereas HIMA, HDMA, and MedFix use a two-step design—the outcome model and mediator models fitted separately—this method fits the models all together, with a jointly penalized likelihood. The penalty not only applies shrinkage to the mediator-outcome associations, like the other methods, but also to the exposure-mediator associations and the mediation contributions.

BSLMM

The Bayesian sparse linear mixed model (BSLMM) is a Bayesian approach proposed by Song et al. (2020)[15]. The model assumes α_a and β_m are random vectors, both independently following mixtures of normal distributions. Most of the effects are presumed to be small, owing to a normal distribution with mean zero and small variance, while the others are allowed to be larger, resulting from a normal distribution with higher variance. We estimate the effects with their posterior mean, and we distinguish

541   active mediators from inactive with their posterior inclusion probability of belonging to the distribution
542   with higher variance.
543
544   **GMM**
545   The Gaussian mixed model (GMM), proposed by Song et al. (2021), is an extension of BSLMM in which
546   the $(\alpha_a)_j$, $(\beta_m)_j$ pairs are treated as correlated, following a mixture of multivariate normal distributions
547   instead of two independent normal distributions[42]. Thus, GMM may be more useful than BSLMM if the
548   true size of each $(\beta_m)_j$ is related to the size of the corresponding $(\alpha_a)_j$, and vice-versa.
549

Group 2 Methods

551   This group of methods directly estimate the global indirect effect without producing estimates of its
552   mediator-specific contributions.
553

554   **PCMA**
555   Principal component mediation analysis (PCMA), proposed by Huan and Pan (2016), was an early
556   method for multiple-mediator mediation using principal component analysis (PCA)[39]. The authors
557   perform PCA on the residual matrix of the mediator models, then use the p by r loading matrix Q to
558   transform the matrix M into a new set of mediators, M^*, which are uncorrelated conditional on A and C.
559   The transformed mediators then replace the original mediators in the analysis, and because they are
560   uncorrelated, the outcome and mediator models can be fit without issue. Although the mediators have
561   been transformed, and the mediator-specific contributions $(\alpha_a)_j(\beta_m)_j$ no longer correspond to the original
562   j^{th} mediator, the global indirect effect $\alpha_a^T \beta_m$ can still be estimated with its original interpretation. The
563   authors set r to equal p, though this is only possible if p is less than n.
564

565   **SPCMA**
566   Zhao et al (2019) proposed sparse principal component analysis (SPCMA) to improve the interpretability
567   of the results from PCMA[40]. In PCMA, the transformed mediators are difficult to interpret because they
568   are sums of all p original mediators; whereas in SPCMA, the loading matrix Q is sparsified, meaning that
569   each transformed mediator is only a sum of a few of the original mediators. The results are easier to
570   interpret because, if a specific transformed mediator has a large effect, it can potentially be traced back to
571   the original mediators which were used to construct it. SPCMA induces bias in its estimation compared to
572   PCMA, but it can be helpful for identifying groups of mediators which may be active.
573

574   **HILMA**
575   High-dimensional linear mediation analysis (HILMA), proposed by Zhou (2020), estimates $\alpha_a^T \beta_m$ with a
576   complex, de-biased penalized regression approach[38]. The mathematics of the procedure are beyond the
577   scope of this text, but the proposed estimator has asymptotic properties for testing whether $\alpha_a^T \beta_m$ is zero,
578   and can also be applied when there are multiple (but not high-dimensional) exposures.
579

Group 3 Methods

581   The last group of methods is fundamentally distinct from the others: Instead of fitting the original
582   mediation models (Group 1), or estimating the mediation effect without fitting the models (Group 2), they
583   reconceptualize the causal structure of the problem to produce results with unique interpretations. Like

584 any method, they should only be applied when their assumptions about the causal structure are
585 reasonable.
586

HDMM

588 High-dimensional multivariate mediation (HDMM), proposed by Chén et al. (2018), is similar to PCMA
589 in that it uses dimension reduction, but chooses the loading vectors with a likelihood-based approach
590 instead of PCA[41]. The loading vectors are referred to as "directions of mediation," each vector specifying
591 a linear combination of mediators which contribute to the likelihood of the mediation models. Hence,
592 HDMM implicitly assumes that there are latent, unmeasured mediating variables that can be represented
593 as linear combinations of the observed mediators. The results of HDMM are difficult to interpret, but it
594 can still be useful for identifying whether there is any mediation through M at all, and for identifying
595 large subsets of mediators that contribute to that mediation.
596

LVMA

598 Latent variable mediation analysis (LVMA), proposed by Derkach et al. (2019), assumes that M itself is
599 not involved in mediation, but rather, that there are a small number of unmeasured mediators, F, which
600 transmit the effect of A to Y and which also cause changes in M[43]. In other words, LVMA assumes
601 explicitly what HDMM assumes implicitly, and the results of the two methods have a similar structure. A
602 key feature of LVMA is that the $F \rightarrow M$ associations are sparsified, meaning that the method can be used
603 for detecting relevant mediators in M. An observed mediator would be considered active if it is associated
604 with a latent mediator that is itself associated with A and Y.
605

Simulation study

Simulation settings

608　　　　We evaluate the above methods with a simulation study. To contrast them under diverse
609 conditions, we consider three different settings of mediation: (1) a baseline setting in which the mediation
610 signals are sparse and the (potential) mediators are moderately correlated, (2) a high-correlation setting
611 with sparse signals, and (3) a moderate correlation setting in which the signals are non-sparse. Within
612 each of these settings, we also vary the degree of mediation by modifying three parameters: the
613 proportion of variance in M that is explained by A among those associated with A (PVE_A), the proportion
614 of the variance of Y that is explained by the direct effect (PVE_{DE}), and the proportion of the variance of Y
615 that is explained by the global indirect effect (PVE_{IE}). For a baseline case, we let PVE_A equal 0.20 and
616 PVE_{DE} and PVE_{IE} both equal 0.10; then, in three additional cases, we sequentially decrease one of these
617 parameters by half, weakening the signal, and set the other two parameters to their values from the
618 baseline. Between Settings (1) to (3), this amounted to 12 unique data-generating mechanisms in total.
619 Each of these was evaluated with a sample size of 1,000 and 2,500, with the number of potential
620 mediators fixed at 2,000. All combinations of settings are listed below in Table 5.
621
622
623
624
625
626
627

628

629

630   **Table 5. Complete list of settings in simulation study**

Number of potential mediators (p)	Sample Size (n)	Sparsity of signals	Degree of correlation	PVE_A	PVE_{IE}	PVE_{DE}
2000	2500	Sparse	Baseline	0.20	0.10	0.10
2000	2500	Sparse	Baseline	0.20	0.05	0.10
2000	2500	Sparse	Baseline	0.10	0.10	0.10
2000	2500	Sparse	Baseline	0.20	0.10	0.05
2000	2500	Sparse	High	0.20	0.10	0.10
2000	2500	Sparse	High	0.20	0.05	0.10
2000	2500	Sparse	High	0.10	0.10	0.10
2000	2500	Sparse	High	0.20	0.10	0.05
2000	2500	Non-sparse	Baseline	0.20	0.10	0.10
2000	2500	Non-sparse	Baseline	0.20	0.05	0.10
2000	2500	Non-sparse	Baseline	0.10	0.10	0.10
2000	2500	Non-sparse	Baseline	0.20	0.10	0.05
2000	1000	Sparse	Baseline	0.20	0.10	0.10
2000	1000	Sparse	Baseline	0.20	0.05	0.10
2000	1000	Sparse	Baseline	0.10	0.10	0.10
2000	1000	Sparse	Baseline	0.20	0.10	0.05
2000	1000	Sparse	High	0.20	0.10	0.10
2000	1000	Sparse	High	0.20	0.05	0.10
2000	1000	Sparse	High	0.10	0.10	0.10
2000	1000	Sparse	High	0.20	0.10	0.05
2000	1000	Non-sparse	Baseline	0.20	0.10	0.10
2000	1000	Non-sparse	Baseline	0.20	0.05	0.10
2000	1000	Non-sparse	Baseline	0.10	0.10	0.10
2000	1000	Non-sparse	Baseline	0.20	0.10	0.05

631

632

633 **Simulated dataset creation**

634   First, to obtain sparse mediation effects for Settings (1) and (2), we assume that 1,920 of the

635 2,000 coefficients $(\alpha_a)_j$ and $(\beta_m)_j$ are zero and the remaining 80 are standard normal. Twenty of the

636 nonzero $(\alpha_a)_j$ and $(\beta_m)_j$ are chosen to overlap and have $(\alpha_a)_j(\beta_m)_j$ not equal to zero. To obtain non-sparse

637 signals for Setting (3), we sample the previously zero coefficients from a normal distribution with mean

638 zero and standard deviation 0.2. (These parameter vectors are sampled only once, at the start of the

639 simulations, so that the global mediation effect is held constant, but we shuffle the mediators in each

640 dataset so that different mediators are assigned the effects each time.) Once we have these, we obtain a

641 single simulated dataset by sampling A_i from a standard normal distribution, then produce M_i from model

642 (4) assuming there are no covariates. We add noise to M_i by sampling residuals from a multivariate

643 normal distribution with mean 0_p and variance Σ, where Σ is derived by shuffling and then tuning the

644 variance-covariance of the observed methylation data (see supplementary section 1). In Settings (1) and

645 (3), we tune Σ so that the correlations between mediators range from -0.37 to 0.49, and in Setting (2), so

646 that they range from -0.58 to 0.75. We fix PVE_A by scaling Σ appropriately based on α_a. Finally, we

647 define Y_i based on model (3) assuming the residuals are Normal$(0,\sigma^2)$, choosing β_a and σ^2 to yield the

648 desired PVE_{DE} and PVE_{IE}.

649

Evaluation

We evaluate the methods by applying them to 100 replicates of each setting in Table 5. We omit SPCMA, GMM, and LVMA for computational reasons, as they are too computationally costly to deploy on so many replicates, and omit HDMM because it does not have an estimand that is comparable to the others. We include a one-at-a-time approach—in which the mediator are assessed individually using traditional mediation analysis and the joint significance test[44]—as a baseline for comparison. When running HIMA, HDMA, MedFix, and pathway LASSO, we pre-screen the mediators to only include the $n/\log(n)$ mediators with the strongest associations with Y adjusting for A, which is the approach recommended by the HIMA and HDMA authors[34,35] (see supplementary section 2 for more details). For comparison metrics, we use (1) the true positive rate for detecting active mediators, TPR $=$ $\frac{\text{number of true mediators identified}}{\text{number of true mediators}}$; (2) the mean squared error in estimating the mediation contributions of inactive mediators, $\text{MSE}_{\text{Inactive}} = \text{mean}_{j:\text{ Inactive}}\left(\left(\widehat{\boldsymbol{\alpha_a}}\right)_j\left(\widehat{\boldsymbol{\beta_m}}\right)_j - (\boldsymbol{\alpha_a})_j(\boldsymbol{\beta_m})_j\right)^2$; (3) the mean squared error in estimating the mediation contributions of active mediators, $\text{MSE}_{\text{Active}} =$ $\text{mean}_{j:\text{ Active}}\left(\left(\widehat{\boldsymbol{\alpha_a}}\right)_j\left(\widehat{\boldsymbol{\beta_m}}\right)_j - (\boldsymbol{\alpha_a})_j(\boldsymbol{\beta_m})_j\right)^2$; and (4) the percent relative bias in estimating the global indirect effect, $\frac{|\widehat{\alpha_a^T\beta_m} - \alpha_a^T\beta_m|}{\alpha_a^T\beta_m} \times 100$. In the non-sparse setting, since all the mediators contribute to the indirect effect, we consider the "active" ones to be those whose mediator-outcome and exposure-mediator effects both come from the distribution with higher-variance, and the others inactive. Each metric is computed for each dataset to the applicable methods, and we report the average and a 95% empirical confidence interval over the 100 replicates.

Scalability comparison

We compare the scalability of the methods by assessing their processing time on simulated datasets of two sizes: one with 100 observations and 200 mediators and one with 1,000 observations and 2,000 mediators. For the larger dataset, we use one of the datasets created for the simulation study, and for the smaller dataset, we subset the rows and columns of M and the entries in A and Y. Run times are assessed on a single core of an Intel(R) Xeon(R) Gold 6242R CPU @ 3.10GHz processor. We attempt each method 30 times and report the mean and interquartile range of the computation times. Since SCPMA and BSLMM tend to be time-consuming, we approximate their run times by downscaling the appropriate parameters: In particular, since the desired number of principal components in SPCMA is 100, we use only 2 principal components and scale the computing time by 50; and since the desired number of posterior samples in BSLMM is 30,000, we draw only 750 samples and scale the result by 40. Ad hoc experimentation confirmed that the methods were approximately linear with respect to these inputs.

# Data application with MESA

To demonstrate how these methods can be applied to observed DNAm data, we evaluate the association between SES and HbA1c and its potential mediation through DNAm. For the exposure, we use a binary variable that indicates low educational attainment (less than a 4-year college degree); for the outcome, we use HbA1c, a continuous variable that reflects average three-month blood glucose level. Our data for this portion come from the Multi-Ethnic Study of Atherosclerosis (MESA), a US population-based longitudinal study[17]. Out of 6,814 total participants, a random subsample of 1,264 had their DNAm

691   measured at 484,882 CpG sites. We limit our analysis to the 963 participants who (1) had methylation
692   data, (2) had no missing data for the required variables, (3) consented to genetic and phenotypic use
693   through the database of Genotypes and Phenotypes (dbGaP) (phs000209.v13.p3), and (4) were not on
694   diabetes medication, which can cause changes in HbA1c (Fig. 6). Standard quality control filters reduced
695   the number of CpG sites to 402,339. Since it is not statistically or computationally feasible to include so
696   many mediators at once, we used a screening procedure to reduce that number further, fitting model (6)
697   below for each mediator separately to choose the 2,000 CpG sites at which DNAm was most strongly
698   associated with education based on the $(\alpha_a)_j$ p-value. These 2,000 formed the baseline set of CpGs for our
699   analysis. DNAm was measured using M-values, defined as the log-2 ratio of the methylated to
700   unmethylated probe intensities, which has the advantage of occurring on a continuous and unbounded
701   scale[56]. For more details see supplementary section 3. A model for the proposed mechanism is given by

702    $$E[\text{HbA1c}_i|\text{Education}_i, \textbf{DNAm}_i, \textbf{Covariates}_i] = \beta_a \text{Education}_i + \boldsymbol{\beta}_m^T \textbf{DNAm}_i + \boldsymbol{\beta}_c^T \textbf{Covariates}_i \quad (5)$$

703   and

704    $$E[\textbf{DNAm}_i|\text{Education}_i, \textbf{Covariates}_i] = \alpha_a \text{Education}_i + \alpha_c \textbf{Covariates}_i, \quad (6)$$

705   where the covariates include age, sex, race, and the estimated proportions of residual non-monocytes (i.e.,
706   neutrophils, B cells, T cells, and natural killer cells) as fixed effects and methylation chip and position as
707   random effects.

708   **Fig. 6. Pre-processing of MESA methylation data.** *Participants who consent to genetic and phenotypic data use,
709   and whose data is available on dbGaP.

710   We performed mediation analysis on the final dataset of 963 individuals and 2,000 CpG sites. All of the
711   mediation methods described above were included except for GMM and LVMA, which again were too
712   costly computationally. Although it is reasonable for some of the methods to include all 2,000 CpG sites
713   directly in the multivariable model, HIMA and HDMA involve sure independence screening[57] to reduce
714   the number of mediators in advance to $n/\log(n)$, where n is the sample size. For the sake of consistency
715   across the penalized regression methods, we do so with not only HIMA and HDMA, but also MedFix and
716   pathway LASSO, including only the 141 (963/log(963)) CpG sites most associated with low education (a
717   direct extension of the initial screening). (Note that, for HIMA and HDMA, this screening is *part* of the
718   proposed method, not separate from it, but for MedFix and pathway LASSO the additional screening is
719   still beneficial for the sake of comparing methods and for statistical and computational efficiency).
720   Additional pre-screening is not necessary for PCMA, SPCMA, BSLMM, and HILMA, and we include all
721   2,000 CpG sites directly; however, in HDMM, which cannot accommodate $p > n$ simplistically, we again
722   use only twice-screened subset of 141 sites. For the sake of comparison with multivariate methods, we
723   also include a one-at-a-time mediation method based on linear regression and the joint significance test.
724   For estimating the total effect, the methods PCMA, SPCMA, BSLMM, and Pathway LASSO all produce
725   estimates of the direct effect, so we can estimate the total effect by summing the estimated direct and
726   global indirect effects. Since the methods HIMA, HDMA, and MedFix do not produce estimates of the
727   direct effect, we first estimate the total effect on its own by fitting model (5) with the mediators excluded,
728   then subtract the estimated global indirect effect from this value to obtain an estimate of the direct effect.
729   As none of the high-dimensional methods are built to directly handle random effects as covariates, we
730   regress these out of the outcome variable and potential mediators in advance. For the fixed effect
731   covariates, HIMA, HDMA, MedFix, and BSLMM allow one to include them directly; whereas in PCMA,
732   SPCMA, HILMA, HDMM, and pathway LASSO, we regressed them out in advance from the outcome
733   and mediators. Continuous variables (including HbA1c and the mediators) were standardized for all
734   methods. All analysis was conducted using R version 4.2.1.
735

Data Availability

737   Data used for the simulation study are available from the authors upon request. Data used in the DNAm
738   analysis can be obtained through the MESA Data Coordinating Center (https://www.mesanhlbi.org/).
739

Code Availability

741   R scripts for the analysis are available at https://github.com/dclarkboucher/mediation_DNAm. Our R
742   package "hdmed" can be found at https://github.com/dclarkboucher/hdmed.
743

References

744   1.   Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. *Neuropsychopharmacol.*
745   *Off. Publ. Am. Coll. Neuropsychopharmacol.* **38**, 23–38 (2013).
747   2.   Kurdyukov, S. & Bullock, M. DNA Methylation Analysis: Choosing the Right Method. *Biology*
748   *(Basel).* **5**, (2016).
749   3.   Dick, K. J. *et al.* DNA methylation and body-mass index: a genome-wide analysis. *Lancet*
750   *(London, England)* **383**, 1990–1998 (2014).
751   4.   Wahl, S. *et al.* Epigenome-wide association study of body mass index, and the adverse outcomes
752   of adiposity. *Nature* **541**, 81–86 (2017).
753   5.   Volkmar, M. *et al.* DNA methylation profiling identifies epigenetic dysregulation in pancreatic

754   islets from type 2 diabetic patients. *EMBO J.* **31**, 1405–1426 (2012).

755   6.   Chilunga, F. P. *et al.* Genome-wide DNA methylation analysis on C-reactive protein among
756   Ghanaians suggests molecular links to the emerging risk of cardiovascular diseases. *NPJ genomic*
757   *Med.* **6**, 46 (2021).

758   7.   Nakatochi, M. *et al.* Epigenome-wide association of myocardial infarction with DNA methylation
759   sites at loci related to cardiovascular disease. *Clin. Epigenetics* **9**, 54 (2017).

760   8.   Fujii, R. *et al.* Dietary fish and ω-3 polyunsaturated fatty acids are associated with leukocyte
761   ABCA1 DNA methylation levels. *Nutrition* **81**, 110951 (2021).

762   9.   Sun, Y. V *et al.* Epigenomic association analysis identifies smoking-related DNA methylation
763   sites in African Americans. *Hum. Genet.* **132**, 1027–1037 (2013).

764   10.   Philibert, R. A., Plume, J. M., Gibbons, F. X., Brody, G. H. & Beach, S. R. H. The impact of
765   recent alcohol use on genome wide DNA methylation signatures. *Front. Genet.* **3**, 54 (2012).

766   11.   Rider, C. F. & Carlsten, C. Air pollution and DNA methylation: effects of exposure in humans.
767   *Clin. Epigenetics* **11**, 131 (2019).

768   12.   Lam, L. L. *et al.* Factors underlying variable DNA methylation in a human community cohort.
769   *Proc. Natl. Acad. Sci. U. S. A.* **109 Suppl**, 17253–17260 (2012).

770   13.   Needham, B. L. *et al.* Life course socioeconomic status and DNA methylation in genes related to
771   stress reactivity and inflammation: The multi-ethnic study of atherosclerosis. *Epigenetics* **10**,
772   958–969 (2015).

773   14.   Fujii, R., Sato, S., Tsuboi, Y., Cardenas, A. & Suzuki, K. DNA methylation as a mediator of
774   associations between the environment and chronic diseases: A scoping review on application of
775   mediation analysis. *Epigenetics* 1–27 (2021) doi:10.1080/15592294.2021.1959736.

776   15.   Song, Y. *et al.* Bayesian shrinkage estimation of high dimensional causal mediation effects in
777   omics studies. *Biometrics* **76**, 700–710 (2020).

778   16.   Du, J. *et al.* Methods for Large-scale Single Mediator Hypothesis Testing: Possible Choices and
779   Comparisons. (2022) doi:10.48550/arxiv.2203.13293.

780   17.   Bild, D. E. *et al.* Multi-Ethnic Study of Atherosclerosis: objectives and design. *Am. J. Epidemiol.*
781   **156**, 871–881 (2002).

782   18.   Whitaker, S. M. *et al.* The Association Between Educational Attainment and Diabetes Among
783   Men in the United States. *American journal of men's health* vol. 8 (2014).

784   19.   Sakurai, M. *et al.* HbA1c and the risks for all-cause and cardiovascular mortality in the general
785   Japanese population: NIPPON DATA90. *Diabetes Care* **36**, 3759–3765 (2013).

786   20.   Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W. & Evans, J. C. Association of
787   HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart
788   Study. *Diabetes* **41**, 202–208 (1992).

789   21.   Yeung, S. L. A., Luo, S. & Schooling, C. M. The Impact of Glycated Hemoglobin (HbA(1c)) on
790   Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank. *Diabetes*
791   *Care* **41**, 1991–1997 (2018).

792   22.   Borghol, N. *et al.* Associations with early-life socio-economic position in adult DNA methylation.
793   *Int. J. Epidemiol.* **41**, 62–74 (2012).

794   23.   Chen, Z. *et al.* DNA methylation mediates development of HbA1c-associated complications in
795   type 1 diabetes. *Nat. Metab.* **2**, 744–762 (2020).

796   24.   Baron, R. M. & Kenny, D. A. The Moderator-Mediator Variable Distinction in Social
797   Psychological Research: Conceptual, Strategic, and Statistical Considerations. *Journal of*
798   *personality and social psychology* vol. 51.

799   25.   MacKinnon, D. *Introduction to statistical mediation analysis.* (New York, NY u.a: Erlbaum).

800   26.   VanderWeele, T. J. Marginal Structural Models for the Estimation of Direct and Indirect Effects.
801   *Epidemiology* **20**, (2009).

802   27.   Pearl, J. Direct and Indirect Effects. in *Proceedings of the Seventeenth Conference on Uncertainty*
803   *in Artificial Intelligence* 411–420 (Morgan Kaufmann Publishers Inc., 2001).

804   28.   Robins, J. M. & Greenland, S. Identifiability and exchangeability for direct and indirect effects.

805   *Epidemiology* **3**, 143–155 (1992).

806   29.   VanderWeele, T. J. Mediation Analysis: A Practitioner's Guide. *Annu. Rev. Public Health* **37**, 17–
807   32 (2016).

808   30.   VanderWeele author., T. *Explanation in causal inference: methods for mediation and interaction.*
809   *Explanation in causal inference: methods for mediation and interaction* (Oxford University Press,
810   2015).

811   31.   Du, J. *et al.* Methods for large-scale single mediator hypothesis testing: Possible choices and
812   comparisons. *Genet. Epidemiol.* **n/a**, (2022).

813   32.   Aung, M. T. *et al.* Application of an analytical framework for multivariate mediation analysis of
814   environmental data. *Nat. Commun.* **11**, 5624 (2020).

815   33.   VanderWeele, T. J. & Vansteelandt, S. Mediation Analysis with Multiple Mediators. *Epidemiol.*
816   *Method.* **2**, 95–115 (2014).

817   34.   Zhang, H. *et al.* Estimating and testing high-dimensional mediation effects in epigenetic studies.
818   *Bioinformatics* **32**, 3150–3154 (2016).

819   35.   Gao, Y. *et al.* Testing Mediation Effects in High-Dimensional Epigenetic Studies. *Front. Genet.*
820   **10**, 1195 (2019).

821   36.   Zhang, Q. High-Dimensional Mediation Analysis with Applications to Causal Gene Identification.
822   *Statistics in biosciences* (2021).

823   37.   Zhao, Y. & Luo, X. Pathway LASSO: pathway estimation and selection with high-dimensional
824   mediators. *Stat. Interface* **15**, 39–50 (2022).

825   38.   Zhou, R. R., Wang, L. & Zhao, S. D. Estimation and inference for the indirect effect in high-
826   dimensional linear mediation models. *Biometrika* **107**, 573–589 (2020).

827   39.   Huang, Y.-T. & Pan, W.-C. Hypothesis test of mediation effect in causal mediation model with
828   high-dimensional continuous mediators. *Biometrics* **72**, 402–413 (2016).

829   40.   Zhao, Y., Lindquist, M. A. & Caffo, B. S. Sparse principal component based high-dimensional
830   mediation analysis. *Comput. Stat. Data Anal.* **142**, 106835 (2020).

831   41.   Chén, O. Y. *et al.* High-dimensional multivariate mediation with application to neuroimaging data.
832   *Biostatistics (Oxford, England)* vol. 19 (2018).

833   42.   Song, Y. *et al.* Bayesian sparse mediation analysis with targeted penalization of natural indirect
834   effects. *J. R. Stat. Soc. Ser. C (Applied Stat.* **70**, 1391–1412 (2021).

835   43.   Derkach, A., Pfeiffer, R. M., Chen, T.-H. & Sampson, J. N. High dimensional mediation analysis
836   with latent variables. *Biometrics* **75**, 745–756 (2019).

837   44.   MacKinnon, D. P., Lockwood, C. M., Hoffman, J. M., West, S. G. & Sheets, V. A comparison of
838   methods to test mediation and other intervening variable effects. *Psychol. Methods* **7**, 83–104
839   (2002).

840   45.   Pedroso, J. A. B., Ramos-Lobo, A. M. & Donato, J. J. SOCS3 as a future target to treat metabolic
841   disorders. *Hormones (Athens).* **18**, 127–136 (2019).

842   46.   Wang, Y. Z. *et al.* DNA Methylation Mediates the Association Between Individual and
843   Neighborhood Social Disadvantage and Cardiovascular Risk Factors. *Front. Cardiovasc. Med.* **9**,
844   848768 (2022).

845   47.   Stage, E. *et al.* The effect of the top 20 Alzheimer disease risk genes on gray-matter density and
846   FDG PET brain metabolism. *Alzheimer's Dement. (Amsterdam, Netherlands)* **5**, 53–66 (2016).

847   48.   Mei, H. *et al.* Tissue Non-Specific Genes and Pathways Associated with Diabetes: An Expression
848   Meta-Analysis. *Genes (Basel).* **8**, (2017).

849   49.   Rahman, S. A., Nessa, A. & Hussain, K. Molecular mechanisms of congenital hyperinsulinism. *J.*
850   *Mol. Endocrinol.* **54**, R119–R129 (2015).

851   50.   Galcheva, S., Al-Khawaga, S. & Hussain, K. Diagnosis and management of hyperinsulinaemic
852   hypoglycaemia. *Best Pract. Res. Clin. Endocrinol. Metab.* **32**, 551–573 (2018).

853   51.   Pedroso, J. A. B. *et al.* Inactivation of SOCS3 in leptin receptor-expressing cells protects mice
854   from diet-induced insulin resistance but does not prevent obesity. *Mol. Metab.* **3**, 608–618 (2014).

855   52.   Senniappan, S., Shanti, B., James, C. & Hussain, K. Hyperinsulinaemic hypoglycaemia: genetic

856   mechanisms, diagnosis and management. *J. Inherit. Metab. Dis.* **35**, 589–601 (2012).

857 53. Huang, Y.-T., Vanderweele, T. J. & Lin, X. Joint analysis of SNP and gene expression data in
858   genetic association studies of complex diseases. *Ann. Appl. Stat.* **8**, 352–376 (2014).

859 54. Zhang, C.-H. Nearly unbiased variable selection under minimax concave penalty. *Ann. Stat.* **38**,
860   894–942 (2010).

861 55. Zhang, S. S. & Zhang, C.-H. Confidence intervals for low dimensional parameters in high
862   dimensional linear models. *Journal of the Royal Statistical Society. Series B, Statistical*
863   *methodology* vol. 76 (2014).

864 56. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying methylation levels
865   by microarray analysis. *BMC Bioinformatics* **11**, 587 (2010).

866 57. Fan, J. & Lv, J. Sure independence screening for ultrahigh dimensional feature space. *J. R. Stat.*
867   *Soc.* **70**, 849–911 (2008).

868

Acknowledgements